Phase 2aData readout

BI-1206 + KEYTRUDA

Treatment-naïve NSCLC patients, uveal melanoma

BINVBioInvent International AB

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: BI-1206 + KEYTRUDA
Development stage: Phase 2a
Event type: Data readout
Indication: Treatment-naïve NSCLC patients, uveal melanoma

Research summary

What is being tracked?

This catalyst tracks a Phase 2a data readout for BI-1206 + KEYTRUDA in Treatment-naïve NSCLC patients, uveal melanoma. The expected timing is based on the latest available company guidance and may change.

Development notes

Q2'25- Initiate trial in H2 2025 & first data read-out in H2 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source